Alexander Hardy
Chief Executive Officer
Replay available
BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) Q2 2026 earnings conference call, held 2026-08-06. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Cristin Hubbard
Chief Commercial Officer
Greg Friberg
Chief R&D Officer
Brian Mueller
Chief Financial Officer
Chris Raymond
Analyst, Raymond James
Corey Casimo
Analyst, Evercore ISI
Jess Bai
Analyst, J.P. Morgan
Selvine Richter
Analyst, Goldman Sachs
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Biomarin Pharmaceutical Inc..
Replay transcript excerpt
WEBVTT 00:00:00.122 -- 00:00:05.664 Good afternoon and welcome everyone to the BioMarin Pharmaceutical second quarter 2026 00:00:05.664 -- 00:00:09.525 conference call. Today's conference is being recorded. 00:00:09.525 -- 00:00:12.787 All lines have been placed on mute to prevent any background noise. 00:00:12.787 -- 00:00:16.228 After the speaker's remarks, there will be a question and answer session. 00:00:16.228 -- 00:00:20.229 If you would like to ask a question during this time, simply press the star key followed 00:00:20.229 -- 00:00:22.890 by the number one on your telephone keypad. 00:00:22.890 -- 00:00:27.011 If you would like to withdraw your question, press star one again. 00:00:27.347 -- 00:00:29.088 Thank 00:00:29.088 -- 00:00:31.088 you, 00:00:32.930 -- 00:00:35.531 Operator, and thank you all for joining us today. 00:00:35.531 -- 00:00:39.753 To remind you, this non-confidential presentation contains forward-looking statements 00:00:39.753 -- 00:00:44.575 about the business prospects of Biomarin Pharmaceutical Inc., including expectations 00:00:44.575 -- 00:00:48.977 regarding Biomarin's financial performance, commercial products, and potential future 00:00:48.977 -- 00:00:52.772 products in different areas of therapeutic research and development. 00:00:52.772 -- 00:00:57.334 Results may differ materially depending on the progress of Biomarin's product programs, 00:00:57.334 -- 00:01:02.517 actions of regulatory authorities, availability of capital, future actions in the pharmaceutical 00:01:02.517 -- 00:01:07.379 market, and developments by competitors. And those factors detailed in Biomarin's filings 00:01:07.379 -- 00:01:13.822 with the Securities and Exchange Commission, such as 10Q, 10K, and 8K reports. 00:01:13.822 -- 00:01:18.185 In addition, w...